{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T07:42:52Z","timestamp":1773474172509,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ferric citrate hydrate (FC), an oral iron product is approved as iron preparation for iron deficiency anemia and phosphate binder for chronic kidney disease (CKD). We investigated whether gastric acid secretion inhibitors (GASI) influenced on iron absorption and phosphate-lowering effects of FC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Two phase 3 studies of FC for treatment of hyperphosphatemia in CKD patients (non-dialysis-dependent, 12\u00a0weeks, and hemodialysis, 52\u00a0weeks), were retrospectively analyzed. Patients were divided into with or without concomitant GASI and levels of iron- and phosphate-related parameters were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In non-dialysis study (FC, 60 patients; placebo, 30 patients), 14 FC patients and 14 placebo patients used GASI. No significant differences were found between the FC and placebo groups for adjusted mean differences (95% CI) of changes from baseline to end of treatment (EOT) in serum ferritin [104.84\u00a0ng\/mL (35.97, 173.71) with GASI vs 145.30\u00a0ng\/mL (96.34, 194.25) without GASI, <jats:italic>P<\/jats:italic>\u2009=\u20090.34], and transferrin saturation (TSAT) [12.56% (\u2212\u20090.83, 25.95) with GASI vs 18.56% (8.15, 28.98) without GASI, <jats:italic>P<\/jats:italic>\u2009=\u20090.49]. In hemodialysis study, 95\/180 patients used GASI. Mean changes (SD) from baseline to EOT in serum ferritin were 166.32\u00a0ng\/mL (153.70) with GASI and 155.16\u00a0ng\/mL (139.47) without GASI, and for TSAT were 16.60% (19.44) with GASI and 16.02% (18.81) without GASI. In both studies, there were no differences in the changes from baseline to EOT in serum phosphate between with and without GASI cohorts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>GASI did not influence on the changes in serum ferritin, TSAT and serum phosphate by FC administration.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11255-022-03287-1","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T16:07:57Z","timestamp":1657642077000},"page":"141-150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Iron absorption and phosphate-lowering effects of ferric citrate hydrate are not influenced by gastric\u00a0acid secretion inhibitors in patients with chronic kidney disease: a retrospective post hoc analysis"],"prefix":"10.1007","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3258-4429","authenticated-orcid":false,"given":"Kyoko","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keitaro","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"3287_CR1","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/gut.10.3.226","volume":"10","author":"A Jacobs","year":"1969","unstructured":"Jacobs A, Miles PM (1969) Role of gastric secretion in iron absorption. Gut 10:226\u2013229","journal-title":"Gut"},{"key":"3287_CR2","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1053\/j.gastro.2016.11.023","volume":"152","author":"JR Lam","year":"2017","unstructured":"Lam JR, Schneider JL, Quesenberry CP, Corley DA (2017) Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology 152:821\u20139.e1","journal-title":"Gastroenterology"},{"key":"3287_CR3","first-page":"411","volume":"96","author":"MC Geokas","year":"1967","unstructured":"Geokas MC, McKenna RD (1967) Iron-deficiency anemia after partial gastrectomy. Can Med Assoc J 96:411\u2013417","journal-title":"Can Med Assoc J"},{"key":"3287_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.679066","volume":"12","author":"J Sandvik","year":"2021","unstructured":"Sandvik J, Bjerkan KK, Gr\u00e6slie H, Hoff DAL, Johnsen G, Kl\u00f6ckner C et al (2021) Iron deficiency and anemia 10 years after Roux-en-Y gastric bypass for severe obesity. Front Endocrinol (Lausanne) 12:679066","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3287_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000348805","volume":"37","author":"A Iida","year":"2013","unstructured":"Iida A, Kemmochi Y, Kakimoto K, Tanimoto M, Mimura T, Shinozaki Y et al (2013) Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification. Am J Nephrol 37:346\u2013358","journal-title":"Am J Nephrol"},{"key":"3287_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2215\/CJN.05170513","volume":"9","author":"K Yokoyama","year":"2014","unstructured":"Yokoyama K, Hirakata H, Akiba T, Fukagawa M, Nakayama M, Sawada K et al (2014) Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol 9:543\u2013552","journal-title":"Clin J Am Soc Nephrol"},{"key":"3287_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1053\/j.jrn.2014.03.006","volume":"24","author":"K Yokoyama","year":"2014","unstructured":"Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y et al (2014) Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis. J Ren Nutr 24:261\u2013267","journal-title":"J Ren Nutr"},{"key":"3287_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000366482","volume":"128","author":"K Yokoyama","year":"2014","unstructured":"Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Hirakata H (2014) JTT-751 for treatment of patients with hyperphosphatemia on peritoneal dialysis. Nephron Clin Pract 128:135\u2013140","journal-title":"Nephron Clin Pract"},{"key":"3287_CR9","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/ndt\/gft483","volume":"29","author":"K Yokoyama","year":"2014","unstructured":"Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y et al (2014) A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transplant 29:1053\u20131060","journal-title":"Nephrol Dial Transplant"},{"key":"3287_CR10","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1053\/j.ackd.2019.05.002","volume":"26","author":"PE Pergola","year":"2019","unstructured":"Pergola PE, Fishbane S, Ganz T (2019) Novel oral iron therapies for iron deficiency anemia in chronic kidney disease. Adv Chronic Kidney Dis 26:272\u2013291","journal-title":"Adv Chronic Kidney Dis"},{"key":"3287_CR11","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40265-019-01125-w","volume":"79","author":"T Ganz","year":"2019","unstructured":"Ganz T, Bino A, Salusky IB (2019) Mechanism of action and clinical attributes of Auryxia\u00ae (Ferric Citrate). Drugs 79:957\u2013968","journal-title":"Drugs"},{"key":"3287_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s12185-021-03123-9","volume":"114","author":"N Komatsu","year":"2021","unstructured":"Komatsu N, Arita K, Mitsui H, Nemoto T, Hanaki K (2021) Efficacy and safety of ferric citrate hydrate compared with sodium ferrous citrate in Japanese patients with iron deficiency anemia: a randomized, double-blind, phase 3 non-inferiority study. Int J Hematol 114:8\u201317","journal-title":"Int J Hematol"},{"key":"3287_CR13","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1159\/000344008","volume":"36","author":"K Yokoyama","year":"2012","unstructured":"Yokoyama K, Hirakata H, Akiba T, Sawada K, Kumagai Y (2012) Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol 36:478\u2013487","journal-title":"Am J Nephrol"},{"key":"3287_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/BF01298866","volume":"36","author":"J Golubov","year":"1991","unstructured":"Golubov J, Flanagan P, Adams P (1991) Inhibition of iron absorption by omeprazole in rat model. Dig Dis Sci 36:405\u2013408","journal-title":"Dig Dis Sci"},{"key":"3287_CR15","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/01.SMJ.0000110405.63179.69","volume":"97","author":"VR Sharma","year":"2004","unstructured":"Sharma VR, Brannon MA, Carloss EA (2004) Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J 97:887\u2013889","journal-title":"South Med J"},{"key":"3287_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.5414\/CNP68093","volume":"68","author":"C Matsunaga","year":"2007","unstructured":"Matsunaga C, Izumi S, Furukubo T, Satoh M, Yamakawa T, Uchida T et al (2007) Effect of famotidine and lansoprazole on serum phosphorus levels in hemodialysis patients on calcium carbonate therapy. Clin Nephrol 68:93\u201398","journal-title":"Clin Nephrol"},{"key":"3287_CR17","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1681\/ASN.V1051090","volume":"10","author":"N Takahashi","year":"1999","unstructured":"Takahashi N, Shoji T, Matsubara K, Hitomi H, Hashimoto M, Kiyomoto H et al (1999) Effect of histamine H2-receptor antagonist on the phosphorus-binding abilities of calcium carbonate and calcium lactate in hemodialysis patients. J Am Soc Nephrol 10:1090\u20131094","journal-title":"J Am Soc Nephrol"},{"key":"3287_CR18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/0886022X.2020.1803085","volume":"42","author":"H Minakuchi","year":"2020","unstructured":"Minakuchi H, Yoshida T, Kaburagi N, Fujino T, Endo S, Takemitsu TY et al (2020) Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients. Ren Fail 42:799\u2013806","journal-title":"Ren Fail"},{"key":"3287_CR19","first-page":"1543","volume":"31","author":"J Komiyama","year":"2015","unstructured":"Komiyama J, Yamane S, Shiota Y, Miyake S, Uehara H, Serigaya T et al (2015) Formulation characteristics of the new phosphate-binder, Riona\u00ae 250 mg. Jpn J Clin Dial 31:1543\u20131549 (ISSN:0910-5808 Japanese)","journal-title":"Jpn J Clin Dial"},{"key":"3287_CR20","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S0016-5085(70)80123-8","volume":"58","author":"MS Wheby","year":"1970","unstructured":"Wheby MS, Suttle GE, Ford KT 3rd (1970) Intestinal absorption of hemoglobin iron. Gastroenterology 58:647\u2013654","journal-title":"Gastroenterology"},{"key":"3287_CR21","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.bbamcr.2012.01.014","volume":"1823","author":"T Ganz","year":"2012","unstructured":"Ganz T, Nemeth E (2012) Hepcidin and iron homeostasis. Biochim Biophys Acta 1823:1434\u20131443","journal-title":"Biochim Biophys Acta"},{"key":"3287_CR22","doi-asserted-by":"publisher","first-page":"8877","DOI":"10.1038\/s41598-019-45335-4","volume":"9","author":"K Yokoyama","year":"2019","unstructured":"Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Ito K, Hanaki K et al (2019) Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study. Sci Rep 9:8877","journal-title":"Sci Rep"},{"key":"3287_CR23","doi-asserted-by":"publisher","first-page":"810","DOI":"10.2215\/CJN.08680811","volume":"7","author":"C Nakano","year":"2012","unstructured":"Nakano C, Hamano T, Fujii N, Matsui I, Tomida K, Mikami S et al (2012) Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol 7:810\u2013819","journal-title":"Clin J Am Soc Nephrol"},{"key":"3287_CR24","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12882-021-02575-9","volume":"22","author":"K Ito","year":"2021","unstructured":"Ito K, Yokoyama K, Nakayama M, Fukagawa M, Hirakata H (2021) Association of fibroblast growth factor 23 and \u03b1-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study. BMC Nephrol 22:374","journal-title":"BMC Nephrol"},{"key":"3287_CR25","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nrneph.2010.84","volume":"6","author":"S Shirazian","year":"2010","unstructured":"Shirazian S, Radhakrishnan J (2010) Gastrointestinal disorders and renal failure: exploring the connection. Nature Rev Nephrol 6:480\u2013492","journal-title":"Nature Rev Nephrol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03287-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-022-03287-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03287-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T11:43:28Z","timestamp":1672659808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-022-03287-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["3287"],"URL":"https:\/\/doi.org\/10.1007\/s11255-022-03287-1","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]},"assertion":[{"value":"16 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kyoko Ito is an employee of Torii Pharmaceutical Co., Ltd. and Keitaro Yokoyama has received honoraria from Japan Tobacco Inc., Torii Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., and Kyowa Kirin Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The two studies that provided data for this study were conducted by Japan Tobacco Inc., in accordance with the principles of the Declaration of Helsinki and the Guidelines for Good Clinical Practice and were registered at the Japan Pharmaceutical Information Center as CTI-111435 (GBA4-4) and CTI-111437 (GBA4-6). Informed consent was obtained from all individual participants before study enrollment [, ].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}